PROTEONOMIX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
3 years
0.00
0.03
5 years
0.000.05
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Cohen
CEO | Chief Executive Officer | 58 | 26/95/26 |
| Director of Finance/CFO | 76 | 02/12/02 | |
Steven Mark Byle
CTO | Chief Tech/Sci/R&D Officer | 55 | 05/09/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roger L. Fidler
BRD | Director/Board Member | 73 | 29/09/29 |
Michael Cohen
CEO | Chief Executive Officer | 58 | 26/95/26 |
Steven Mark Byle
CTO | Chief Tech/Sci/R&D Officer | 55 | 05/09/05 |
Stromacel Inc. is a biotechnology company. The Company is a subsidiary of Proteonomix Inc. It offers technology in the field of cellular medicine to international clients. The Company intends to conduct phased human studies of its cellular materials in application to the treatment of cardiac and other diseases.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 0 | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- PROT Stock
